Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03879837 · ClinicalTrials.gov registry record · Phase 3
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,902
- Enrollment target
NCT03879837: Completed Phase 3 study, sponsored by Actavis.
NCT03879837 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 1,902 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (146% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03879837, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,902 participants
- Enrollment target
Study Summary
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma.
Interventions
- DRUG Fluticasone propionate pressurized metered dose inhaler
- DRUG Flovent HFA pressurized metered dose inhaler
- DRUG Placebo pressurized metered dose inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,902 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2021-07-09 |
| Phase | Phase 3 |
What the finished NCT03879837 record still lists
NCT03879837 is an interventional study that assigns participants to a tested intervention. Its 1,902 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (146% higher).
The record links to 0 conditions, and to 3 interventions - of which Fluticasone propionate pressurized metered dose inhaler is the first listed.
NCT03879837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03879837 about?
NCT03879837 is a clinical study titled "Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg". A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma.
What is the current status of trial NCT03879837?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,902 participants. The study started on 2019-03-25. Estimated completion is 2021-07-09.
What interventions are being tested in trial NCT03879837?
The interventions under investigation include: Fluticasone propionate pressurized metered dose inhaler (DRUG), Flovent HFA pressurized metered dose inhaler (DRUG), Placebo pressurized metered dose inhaler (DRUG).
Who is sponsoring clinical trial NCT03879837?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03879837's enrollment target sits among peer trials
1,902 110th of 2000 higher than 1,891 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- NCT07228234 · 1,900 participants · NA
Evaluating Mammography Communication Approaches
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI